Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy


Charcot-Marie-Tooth disease (CMT) is a length-dependent peripheral neuropathy. The aminoacyl-tRNA synthetases constitute the largest protein family implicated in CMT. Aminoacyl-tRNA synthetases are predominantly cytoplasmic, but are also present in the nucleus. Here we show that a nuclear function of tyrosyl-tRNA synthetase (TyrRS) is implicated in a Drosophila model of CMT. CMT-causing mutations in TyrRS induce unique conformational changes, which confer capacity for aberrant interactions with transcriptional regulators in the nucleus, leading to transcription factor E2F1 hyperactivation. Using neuronal tissues, we reveal a broad transcriptional regulation network associated with wild-type TyrRS expression, which is disturbed when a CMT-mutant is expressed. Pharmacological inhibition of TyrRS nuclear entry with embelin reduces, whereas genetic nuclear exclusion of mutant TyrRS prevents hallmark phenotypes of CMT in the Drosophila model. These data highlight that this translation factor may contribute to transcriptional regulation in neurons, and suggest a therapeutic strategy for CMT.


Charcot-Marie-Tooth (CMT) disease, also known as hereditary motor and sensory neuropathy, is the most common hereditary neuromuscular condition affecting 1 in 2500 individuals1. The disease is characterized by weakness and wasting of the distal limb muscles leading to progressive motor impairment, sensory loss, and skeletal deformities. CMT patients typically develop slowly progressive disability early in life, while there is no causal treatment available.

CMT is one of the most heterogeneous Mendelian disorders, with causal mutations in over 80 genes known so far. Notably, CMT gene products are implicated in diverse cellular pathways and their function related to the disease is not always apparent. A prominent example are aminoacyl-tRNA synthetases (aaRSs). With six members involved, they represent the largest family of proteins implicated in the etiology of peripheral neuropathies2,3. aaRSs are ubiquitously expressed enzymes catalyzing the charging of tRNAs with their cognate amino acids and are therefore indispensable for viability. The specific sub-population of neurons affected in CMT sharply contrasts with the broad requirement of aaRSs for protein biosynthesis, indicating that the impact of aaRSs in peripheral nerves may not be limited to protein translation.

In addition to their well characterized localization in the cytoplasm, aaRSs are detected in the nucleus of eukaryotic cells. While the early hypothesis was that nuclear aaRSs function in proofreading newly-synthesized tRNAs4,5,6, later findings suggest that they are involved in regulating a wide range of biological processes including vascular development, inflammation, and stress responses mainly due to their peculiar abilities to interact with the transcriptional machinery7,8,9. For example, we identified the nuclear localization signal in human tyrosyl-tRNA synthetase (TyrRS or YARS) and demonstrated its presence in the nucleus under oxidative stress to transcriptionally upregulate the expression of DNA damage response genes8,10. Overexpression of TyrRS strongly protects against UV-induced DNA damage in zebrafish, whereas restricting TyrRS nuclear entry abolishes this effect. The beneficial effect of nuclear TyrRS is mediated by activating the transcription factor E2F1.

Notably, TyrRS is one of the aaRSs causally linked to CMT disease. Five pathogenic dominant mutations have been reported so far, all of them located in the catalytic domain of the enzyme11,12,13. Three have been extensively characterized both in vitro and in vivo and the results show that a defect in aminoacylation activity is not a shared property (i.e., TyrRS-G41R is enzymatically inactive, while TyrRS-E196K is fully active, and TyrRS-Δ153-156VKQV has partial activity), suggesting that a simple loss of canonical function is not a prerequisite for the disease to occur14. Pathogenicity of these three mutations has been recapitulated in transgenic Drosophila models displaying progressive loss of motor abilities, electrophysiological neuronal dysfunction, and terminal axonal degeneration15. Flies expressing the enzymatically intact TyrRS-E196K mutant show comparable or, in some aspects, more pronounced features of neurodegeneration than flies expressing the aminoacylation compromised mutants, therefore indicating that a gain of toxic function or interference with a non-enzymatic function of the wild type (WT) protein is likely underlying the disease15.

In this study, we set out to investigate how this neurotoxic function is generated from a molecular perspective. Because neuronal identity and maintenance are largely controlled by transcriptionally regulated programs16, we further investigated whether the nuclear localization and function of TyrRS plays any role in the disease mechanism of CMT. We show that CMT-causing mutations in TyrRS induce unique conformational changes, provoking aberrant interactions. These interactions in the nucleus lead to transcription factor E2F1 hyperactivation. Furthermore, a broad transcriptional regulation network associated with wild-type TyrRS expression in Drosophila is disturbed when a CMT-mutant is expressed. Excluding mutant TyrRS from the nucleus using pharmacological and genetic approaches suppresses the CMT hallmark phenotypes of CMT in the Drosophila model. These data highlight that TyrRS may contribute to transcriptional regulation in neurons, and suggest a therapeutic strategy for CMT.


Conformational changes and altered functionalities of TyrRS

In a previous work, we demonstrated that the three established CMT-causing TyrRS mutants (TyrRS-E196K, TyrRS-G41R, and TyrRS-Δ153-156VKQV) induce a conformational opening and expose a consensus area in the catalytic domain of the enzyme17 (Fig. 1a, b). In order to link this unique structural change to specific interactional and functional consequences related to CMT, we included two control mutants in this study. An alternative conformational change can be induced by a rationally designed mutation in the anticodon binding domain (Y341A) to expose a different area of the catalytic domain that is responsible for a “cytokine”-like activity of TyrRS18. Separately, an established benign polymorphism in the anticodon binding domain (K265N) was included, because it shows no toxicity of the protein in human or when overexpressed in Drosophila and we found that it does not trigger any conformational change19 (Fig. 1a, b).

Fig. 1

TyrRS mutations induce structural changes leading to aberrant transcription regulation. a Domain structure of human TyrRS and the location of the different mutations. Red indicates CMT-causing mutations, blue indicates the cytokine-activating Y341A mutation, and orange indicates the benign substitution K265N. b Schematic illustration of the conformational changes induced by the different mutations in TyrRS. c, d Interaction of TyrRS with TRIM28 (c) and HDAC1 (d) detected by Co-IP in HEK293T cells expressing different TyrRS proteins. e Immunoprecipitation of TRIM28 and the associated binding of E2F1 to the regulatory complex upon expression of different TyrRS alleles. f Acetylation levels of E2F1 after IP in HEK293T cells expressing TyrRS. One-way ANOVA with Dunnett Multiple Comparisons test. g, h Expression of E2F1 target genes (BRCA1, RAD51, RAD51L1, and RAD9A) in HEK293T cells expressing different TyrRS alleles (g), and patient-derived and control PBMCs (h). G41R (n = 3 individuals), E196K (n = 2 individuals), and control (n = 5 individuals). n = 3 independent biological replicates, unpaired t-test. Bar charts are presented as means ± s.e.m. Source data are provided as a Source Data file

Previously, we have found that nuclear TyrRS binds to the scaffolding protein TRIM288. Together, they form a complex with the deacetylase HDAC1 in order to regulate the acetylation level and activity of transcription factors such as E2F1 (Supplementary Fig. 1a). To evaluate how different structural perturbations affect the TyrRS-TRIM28 interaction, we co-expressed the neurotoxic TyrRS mutants (TyrRS-E196K, TyrRS-G41R, and TyrRS-Δ153-156VKQV) or the controls (TyrRS-WT, TyrRS-K265N, and TyrRS-Y341A), together with TRIM28 in HEK293T cells. Our previous studies have suggested that the nuclear localization of TyrRS and its response to oxidative stress are shared among different cell types including HEK293T and motor neuron cells8. Immunoprecipitation of TRIM28 revealed co-purification of TyrRS-WT as expected. The CMT-causing mutations enhanced the cellular TyrRS-TRIM28 and TyrRS-HDAC1 interactions (Fig. 1c, d). In contrast, the TyrRS-Y341A mutation resulted in a reduction of the TyrRS-TRIM28/HDAC1 binding, consistent with our previous finding8, while the benign mutation had no effect on the binding properties, just like the TyrRS-WT protein (Fig. 1c, d). These results demonstrate that the CMT-causing mutants have specific binding properties due to its unique conformational change. We also evaluated the TyrRS-TRIM28 interaction in CMT patient derived peripheral blood mononuclear cells (PBMC) that express the mutant protein in the patients’ unique genetic background. The TyrRS-TRIM28 interaction does appear to be stronger in CMT patients’ PBMCs endogenously expressing either TyrRS-E196K or TyrRS-G41R mutant alleles (Supplementary Fig. 1b, c). However, the increase did not convey statistical significance given the small number of patient samples available.

Next, we tested if the strengthened TyrRS-TRIM28 interaction would affect the TRIM28/HDAC1 complex to bind its substrate transcription factors (e.g., E2F1) (Supplementary Fig. 1a). Indeed, a reduced TRIM28-E2F1 interaction was concurrent with the enhanced TyrRS-TRIM28 interaction in HEK293T cells expressing each of the three neurotoxic TyrRS alleles (Fig. 1e). As a result, E2F1 was alleviated from deacetylation by HDAC1, and E2F1 acetylation levels were increased (Fig. 1f). Contrarily, the TRIM28-E2F1 interaction was enhanced in cells expressing TyrRS-Y341A, leading to a decrease in E2F1 acetylation, while we observed no alterations when the K265N variant was expressed (Fig. 1e, f). These data further demonstrate that the uniquely altered binding properties of CMT mutants have a specific functional impact on their interacting partners.

CMT-causing mutant TyrRS overactivates E2F1

Acetylation of E2F1 leads to its activation in human cells20. We examined the downstream effect of mutant TyrRS on four E2F1 transcriptional targets sensitive to nuclear TyrRS (BRCA1, RAD51, RAD51L1, RAD9A) in mammals8. RT-qPCR analysis in HEK293T cells revealed upregulation of these genes in response to TyrRS-E196K overexpression, which was significantly higher than the response to TyrRS-WT (Fig. 1g). Likewise, we observed a significant increase in E2F1-regulated transcription in CMT patients’ PBMCs endogenously expressing mutant TyrRS (Fig. 1h). This upregulation was not due to differences in TyrRS nuclear occupancy, as both HEK293T cells expressing TyrRS-WT or any of the three CMT mutants (G41R, Δ153-156VKQV, E196K), and patient derived PBMCs showed comparable presence of the protein in the nucleus (Supplementary Fig. 2a, b). Thus, via their aberrant interaction properties, CMT-causing mutants behave as hypermorphs regarding their effect on E2F1 activity in mammalian cells.

Next, we explored the relevance of TyrRS-mediated E2F1 overactivation in our Drosophila model for CMT. High expression of TyrRS-E196K in the retina of Drosophila (GMR-Gal4 driver) is toxic and induces a mild rough eye phenotype. In contrast, low expression of TyrRS-WT or TyrRS-E196K shows no retinal disorganization15 (Fig. 2a–c), but serves as a sensitized background for testing TyrRS-genetic interactors. Expression of the fly orthologue of E2F1 (dE2F1), or its co-factor Dp alone, together with either TyrRS transgene had no effect on the retinal morphology (Fig. 2d–i). However, overexpression of dE2F1 together with Dp induced a rough eye on its own, which remained unaltered in the presence of TyrRS-WT (Fig. 2j, k). In contrast, co-overexpression with TyrRS-E196K aggravated the dE2F1-Dp retinal phenotype as quantified by the reduced eye size on top of the severe rough eye phenotype (Fig. 2l, Supplementary Fig. 3a). The phenotype aggravation is unlikely due to additive toxic effects, considering the lack of any morphological phenotypes upon low level of retinal TyrRS-E196K expression alone (Fig. 2c)15. Rather, the result is suggestive of a genetic interaction between TyrRS-E196K and the dE2F1-Dp complex in the fruit fly, consistent with our findings in mammalian cells.

Fig. 2

Modulation of E2F1 activity does not rescue disease hallmarks in the TyrRS Drosophila model. ac Retinas of control flies (GMR-Gal4>+) (a), flies expressing TyrRS-WT (b), and TyrRS-E196K (c) do not display a rough eye phenotype. dl Retinas of flies with a control or TyrRS background that overexpress dE2F1 (df), Dp (gi), and the combination of both transcription factors (jl). Scale bars, 50 µm. m Acetylation of E2F1 after activators of Sirtuin1 (resveratrol (Res)) and HDAC1 (dexamethasone (Dex)) were administered to HEK293T cells expressing different TyrRS alleles. n = 3 independent biological replicates, one-way ANOVA with Dunnett Multiple Comparisons test. Bar charts are presented as means ± s.e.m. n Pupae formation as an indicator of developmental lethality when Drosophila ubiquitously expressing (Act5C-Gal4) TyrRS-E196K were grown on resveratrol or dexamethasone. Res and Dex were dissolved in 0.3% DMSO (42 mM). Number of counted flies (n) are indicated above the chart, χ2-test. o Climbing performance of flies pan-neuronally expressing (nSyb-Gal4) TyrRS-E196K when grown on food containing a combination of resveratrol and dexamethasone. Res and Dex were dissolved in 0.3% DMSO (42 mM). n ≥ 10 independent groups of flies, one-way ANOVA with Dunnett Multiple Comparisons test. Box plots show the median, 25–75% percentiles, and 1.5 interquartile range. Source data are provided as a Source Data file

Inhibition of E2F1 does not rescue TyrRS neurotoxicity in Drosophila

The overactivation of E2F1 is dependent on its acetylation and may be modulated by activators of known E2F1 deacetylases such as Sirtuin 1 (SIRT1) and HDAC121,22. Indeed, treating HEK293T cells expressing TyrRS-WT or TyrRS-E196K with the HDAC1 activator dexamethasone23 or SIRT1 activator resveratrol24 resulted in reduced acetylation levels of E2F1, and the combination of both compounds had a synergistic effect (Fig. 2m). Notably, both drugs affect E2F1 through SIRT1 and HDAC1 specifically, as treatment with either of them in the absence of HDAC1 or SIRT1 (shRNA mediated knockdown) no longer had an effect on E2F1 acetylation (Supplementary Fig. 3b, c).

The success in using dexamethasone and resveratrol to inhibit E2F1 acetylation in cellulo encouraged us to test these compounds in our Drosophila CMT model. Ubiquitous expression (Act5C-Gal4 driver) of the TyrRS-E196K allele induces lethality, as flies have reduced eclosion and pupae formation rates15,19. This developmental phenotype is amendable for drug screening and therefore we raised the mutant flies on food containing 100 µM dexamethasone, resveratrol, or both. A small but significant increase in pupae formation was observed upon feeding dexamethasone or the combination of both drugs (Fig. 2n). We then investigated the pharmaceutical effect on the locomotor behavior of the treated flies. Pan-neuronal (nSyb-Gal4 driver) expression of TyrRS-E196K induces severe motor phenotype, which mimics the motor impairment present in the CMT patients, as flies have difficulties climbing a vertical wall15,25. No improvement of this climbing deficit was observed upon administration of resveratrol and dexamethasone (Fig. 2o and Supplementary Fig. 3d). Thus, pharmacological inhibition of E2F1 slightly reduces the overall toxicity of TyrRS-E196K, however it is insufficient to rescue the CMT-related phenotypes in Drosophila. Due to technical difficulty in detecting E2F1 acetylation in Drosophila tissues, we cannot rule out the possibility that the used drugs were not efficient in suppressing E2F1 in the animal. Alternatively or additionally, we speculate that this negative result indicates the neurotoxic effect of the mutant is broader than E2F1 overactivation.

TyrRS-specific regulatory network altered by a CMT mutant

Next to TRIM28 and HDAC1, our earlier proteomic studies identified a number of additional nuclear proteins as potential interacting partners of TyrRS-WT in non-neuronal mammalian cells8. To assess the full spectrum of downstream effects triggered by TyrRS and its aberrant interactions, we performed expression profiling on whole brains of control (nSyb-Gal4>+), TyrRS-WT, and TyrRS-E196K flies that were aged for 10 days. We opted to study the TyrRS-E196K mutant protein as it does not interfere with the aminoacylation function of the protein and induces the strongest phenotypes in most Drosophila assays14,15. In the transcriptome of TyrRS-WT overexpressing flies, 707 genes were differentially expressed compared to the genetic control (nSyb-Gal4>+) (Fig. 3a). These genes were associated with protein folding, cellular stress response, among others, as suggested by the gene ontology (GO) analysis (fgsea26), see Supplementary Table 1. Transcription factor (TF) predictions (iRegulon27) of both upregulated and downregulated genes identified shared regulatory sequences (E-score >2.5) among the TyrRS-WT regulated genes that are recognized by 38 unique TFs (Supplementary Table 2). Among them was dE2F1, which was in agreement with our previous results, as well as gem, the Drosophila orthologue of TFCP2, a protein identified as an interaction partner of TyrRS in the nucleus of HEK293T cells8 (Fig. 3b). Thus, the overexpression and the nuclear presence of TyrRS-WT is associated with a network of genes regulated by a multitude of TFs.

Fig. 3

Mutant TyrRS induces broad transcriptional changes in Drosophila brain tissues. a Volcano plot of log2 fold change versus mean comparing the TyrRS-WT (nSyb>TyrRS-WT) with the control condition (nSyb>+). b Enriched motifs for the dE2F1 and gem transcription factors identified in the upregulated and downregulated genes of the TyrRS-WT condition, respectively. E-score, enrichment score. c Volcano plot of log2 fold change versus mean comparing the TyrRS-E196K (nSyb>TyrRS-E196K) with the control condition. d Venn diagram displaying the overlap between TyrRS-WT and TyrRS-E196K differentially expressed genes. RF, representation factor. p, associated probability. e Heat map of top 151 differentially expressed genes in the TyrRS-E196K specific 415-gene cluster from brains of Drosophila pan-neuronally (nSyb-Gal4) expressing the indicated transgenes. High expression is shown in red and low expression is shown in blue (z-scores). f TFs identified in the TyrRS-E196K specific gene cluster. TFs associated with the downregulated genes are depicted in blue and those associated with the upregulated set are shown in red. The overlapping TFs are indicated in yellow

Next, we investigated the implications of expressing the TyrRS-E196K mutant on the transcriptome of Drosophila. A total of 830 differentially expressed genes were identified, compared to the genetic control condition (Fig. 3c). GO analysis revealed an enrichment for processes such as neuromuscular synaptic transmission, cellular response to heat, integrin mediated signaling, and protein folding (Supplementary Table 3). A significant overlap was observed between the transcripts differentially expressed in the brains of mutant versus wild-type flies (Fig. 3d). While GO terms overlap between both conditions, there were some distinct differences (Supplementary Fig. 4a and Supplementary Table 4). Of note was the enrichment of neuromuscular synaptic transmission in the E196K condition (Supplementary Fig. 4a).

In addition, weighted gene co-expression network analysis28 identified one cluster (out of 39 in total) of 415 genes that were co-regulated in a unique manner in the TyrRS-E196K expressing flies only (Fig. 3e, Supplementary Fig. 4b). In this cluster, 227 and 188 genes were upregulated or downregulated, respectively, and the dysregulation of selected candidates was confirmed by RT-qPCR (Supplementary Table 5). iRegulon analysis predicted 53 TFs regulating this gene set (Fig. 3f and Supplementary Table 6). One of the TFs associated with the upregulated genes was dE2F1, for which we already demonstrated experimentally its enhanced activity in a CMT-background and the mechanism behind. Fourteen of the predicted TFs (including dE2F1) were common to both TyrRS-E196K and TyrRS-WT conditions (Supplementary Fig. 4c). This overlap is higher than expected by chance, suggesting that part of the transcript dysregulation observed in the mutant flies is tied to the activity of the WT TyrRS. Notably, 39 additional TFs were linked to the TyrRS-E196K activity only and their function was associated with dendrite morphogenesis, neuronal development and glucose metabolism, among others (Supplementary Table 7) (DAVID29,30). This suggests that the transcriptional impact of the CMT-mutant also has a neomorphic component. Overall, our transcriptome analysis indicates that the CMT-mutant TyrRS affects not only E2F1 but could have a broader impact on the transcriptional landscape in the neurons of the Drosophila model.

Inhibition of nuclear TyrRS import alleviates neurotoxicity

In order to demonstrate that the dysregulation in the nucleus by the CMT-mutant is linked to the disease mechanism and knowing that this dysregulation involves multiple genes and associated TFs, we applied a general strategy for alleviating the TyrRS neurotoxicity via inhibiting its nuclear import both genetically and pharmacologically. Nuclear localization of TyrRS is promoted by acetylation, which is mediated by the p300/CBP associated factor (PCAF)31. Thus, we attempted to exclude TyrRS from the nucleus using PCAF inhibitors, such as embelin32. HEK293T cells showed a dose-dependent reduction in nucleus-localized TyrRS upon titration of embelin (Fig. 4a). These results were confirmed in our Drosophila model for CMT, as titration of embelin reduced the nuclear localization of TyrRS (Fig. 4b).

Fig. 4

Pharmaceutical exclusion of TyrRS from the nucleus partially rescues the toxicity of TyrRS mutants. a, b Subcellular localization of TyrRS after treatment with different concentrations of embelin (Emb) in HEK293T cells (14 mM DMSO) (a) and in flies pan-neuronally (nSyb-Gal4) expressing TyrRS (42 mM DMSO) (b). Emb was dissolved in DMSO, which has no effect on TyrRS nuclear localization. α-Tubulin and Lamin served as cytoplasmic and nuclear markers, respectively. n ≥ 3 independent biological replicates, one-way ANOVA with Dunnett Multiple Comparisons test. Bar charts presented as means ± s.e.m. c Pupae formation of Drosophila ubiquitously (Act5C-Gal4) expressing TyrRS-E196K after administration of different concentrations of embelin. Emb was dissolved in 0.3% DMSO (42 mM). Percentages indicate ratio of pupae expressing the TyrRS transgene or not. Dashed line, expected 50:50 pupation rate in the control condition (no transgene). Number of counted pupae (n) are indicated above the chart χ2-test. d Climbing performance of flies pan-neuronally (nSyb-Gal4) expressing TyrRS-E196K raised on food containing Emb, dissolved in 0.3% DMSO (42 mM). n ≥ 10 independent groups of flies. One-way ANOVA with Dunnett Multiple Comparisons test. Box plots show the median, 25–75% percentiles, and 1.5 interquartile range. Source data are provided as a Source Data file

We utilized the previously described developmental lethality assay to investigate the effect of embelin on TyrRS-E196K toxicity in Drosophila. A beneficial, dose-dependent drug effect, much stronger than that of dexamethasone and resveratrol, was observed in this experimental paradigm (Fig. 4c). Next, we tested whether embelin would improve the motor performance of flies pan-neuronally (nSyb-Gal4 driver) expressing TyrRS-E196K. Indeed, at 50 µM and 100 µM concentrations, embelin treated mutant flies climbed significantly faster than untreated animals (Fig. 4d and Supplementary Fig. 5a). Control flies treated with only DMSO or embelin showed no changes in their climbing speed, indicating that embelin did not generally improve climbing behavior of Drosophila (Supplementary Fig. 5b). These results show that pharmacological treatment with inhibitors of nuclear entry of TyrRS could partially alleviate the symptoms in the TyrRS-induced CMT model.

The pharmacological restriction of TyrRS nuclear translocation by embelin was not complete (Fig. 4b) and could explain the partial rescue of disease phenotypes in Drosophila. As an alternative strategy, we altered the nuclear localization signal (NLS) of TyrRS (242KKKLKK247) to a less charged sequence (242NNKLNK247) (hereafter called TyrRS∆NLS) on both WT and E196K-mutated constructs. We thereby successfully restricted the nuclear import of the ectopically expressed TyrRS proteins in HEK293T cells (Supplementary Fig. 6a). It is worth noting that the NLS is conserved in TyrRS from humans to insects and TyrRS∆NLS maintains robust enzymatic activity10, and could therefore be used to study the TyrRS nuclear function without impacting translation in the cytoplasm. Indeed, while all pan-neuronally (nSyb-Gal4 driver) expressed human transgenes have comparable expression levels (except for WT TyrRS∆NLS with slightly lower expression) (Supplementary Fig. 6b), the nuclear localization of TyrRS∆NLS is diminished for both WT TyrRS and the CMT mutant in the Drosophila neurons (Fig. 5a). Even for WT TyrRS, the nuclear fraction is very small compared with the cytoplasmic fraction (Supplementary Fig. 6c), therefore the change in nuclear localization would not significantly affect the amount of TyrRS in the cytoplasm. As such, we have established matching TyrRS and TyrRS∆NLS expression systems to genetically study nuclear TyrRS and its link to the CMT pathology.

Fig. 5

Genetic nuclear exclusion of mutant TyrRS fully prevents disease phenotypes in Drosophila (a) Subcellular localization of TyrRS in heads of flies pan-neuronally (nSyb-Gal4) expressing different TyrRS alleles. ΔNLS, disrupted NLS motif by mutating 242KKKLKK247 to 242NNKLNK247. α-Tubulin and Lamin served as cytoplasmic and nuclear markers, respectively. n = 3 independent biological replicates, bar charts presented as means ± s.e.m. b Eclosion rates of flies ubiquitously expressing (Act5C-Gal4) no transgene (Control) or different TyrRS-alleles. Dashed line, expected 50:50 eclosion rate in the control condition (no transgene). Number of counted flies (n) are indicated above the bars, χ2-test. c Negative geotaxis assay comparing the motor performance of Drosophila pan-neuronally (nSyb-Gal4) expressing no transgene (Control) or different TyrRS alleles. n ≥ 10 groups of flies. One-way ANOVA with Dunnett Multiple Comparisons test. d NMJ’s of wandering third instar larvae pan-neuronally (nSyb-Gal4) expressing no transgene (Control), TyrRS-WT, TyrRS-WTΔNLS, TyrRS-E196K or TyrRS-E196KΔNLS. HRP, neuronal membrane marker; Dlg1, post-synapse marker. Scale bar, 20 µm. e, f Quantification of total length of the NMJ (e) and total number of boutons (f). n ≥ 10 larvae for each genotype. One-way ANOVA with Dunnett Multiple Comparisons test. g Dye injections reveal the morphology of the giant fiber terminals in flies expressing (R91H05-Gal4) different TyrRS alleles cell autonomously in the giant fibers. Scale bar, 20 µm. h The ability of the giant fiber to follow repeated stimuli at 100 Hz upon presynaptic (R91H05-Gal4) expression of different TyrRS alleles in the giant fiber. n ≥ 20 tergotrochanteral muscles (TTMs) of flies aged to 10 days. One-way ANOVA with Dunnett Multiple Comparisons Test. Box plots show the median, 25–75% percentiles, and 1.5 interquartile range. Source data are provided as a Source Data file

First, we tested for any general cytotoxicity effect of TyrRS-WT∆NLS upon ubiquitous expression, using the developmental lethality assay. Drosophila ubiquitously (Act5C-Gal4 driver) expressing TyrRS-WT or TyrRS-WT∆NLS eclosed similarly to the non-transgenic control (Fig. 5b). Remarkably, eclosion rates of animals expressing TyrRS-E196KΔNLS were also inconspicuous, suggesting that restriction of mutant protein in the cytoplasm is sufficient to prevent its toxicity (Fig. 5b). Similarly, pan-neuronal (nSyb-Gal4 driver) expression of TyrRS-E196K∆NLS did not cause any locomotor deficits as opposed to the significant climbing impairment observed in the presence of TyrRS-E196K (Fig. 5c and Supplementary Fig. 6d).

We further tested the effect of TyrRS-E196K∆NLS expression on the morphology of the Drosophila larval neuromuscular junction (NMJ). This synapse is likely the first site of lesion in the dying-back type of neuropathies and has been studied extensively in different CMT fly and mouse models25,33,34. To this end, we pan-neuronally expressed (nSyb-Gal4 driver) different TyrRS transgenes and measured the number of neuronal contact sites (synaptic boutons) and the length of the NMJ. The total length of the neuronal arbor of TyrRS-E196K larvae were smaller and had fewer boutons compared to controls (Fig. 5d-f and Supplementary Fig. 6e, f), showing that NMJ morphology and length are altered upon expression of mutant TyrRS. In contrast, exclusion of TyrRS-E196K from the nucleus resulted in regular NMJ appearance. Excitingly, the transcription fingerprint of TyrRS-WT∆NLS and TyrRS-E196K∆NLS brains clustered together with the control animals (Fig. 3e and Supplementary Fig. 4b), providing a mechanistic basis for the observed functional rescue. Taken together, our characterization of the TyrRS-E196K∆NLS flies at transcriptome, morphological, behavioral, and organismal levels provided strong evidences that the nuclear presence of mutant TyrRS is important for the CMT disease mechanism.

Lastly, to further evaluate the impact of the nuclear mutant TyrRS on CMT neuropathology, we assessed the morphology and synaptic transmission of the Drosophila Giant fibers (GFs), containing one of the longest axons in adult flies. We previously used these in the Drosophila TyrRS-CMT model and established that the TyrRS-Δ153-156 mutation provokes the strongest GF phenotypes15. Using the R91H05-Gal4 line, we assessed the impact of the cell autonomous expression of different TyrRS proteins in the GFs. Dye injections (Fig. 5g) and electrophysiological recordings (Fig. 5h and Supplementary Fig. 6g) revealed no morphological differences between GF terminals of TyrRS-WT and TyrRS-WT∆NLS expressing flies. In contrast, expression of TyrRS-∆153-156 induced degeneration of the GF terminals (Fig. 5g), which was associated with the reduced ability of the GF synapse to follow repetitive stimuli (Fig. 5h and Supplementary Fig. 6g). Notably, exclusion of the mutant protein from the nucleus (TyrRS-∆153-156∆NLS) did not provoke these morphological and functional synaptic phenotypes (Fig. 5g, h, and Supplementary Fig. 6g). These results strongly suggest that the GF phenotypes caused by TyrRS-∆153-156 require its nuclear localization, further supporting that CMT pathology is associated with a dysfunction of mutant TyrRS in the nucleus.


Understanding the pathogenic mechanisms behind the largest protein family linked to CMT, the most common hereditary neuromuscular disorder, imposes a major challenge for both the neuropathy and the tRNA synthetase fields. We and others extensively studied in vitro and in vivo the canonical enzymatic function of aaRSs in relation to CMT and excluded a loss-of-function disease mechanism, at least for two of them (glycyl-tRNA synthetase (GlyRS) and TyrRS)25. Although it becomes more and more clear that mutations in these genes cause CMT phenotypes through a toxic gain-of-function mechanism15,35,36, the molecular and functional aspects of this mechanism remain elusive.

Using a bottom up approach, this study stemmed from our previous understanding of the unique structural changes induced by the CMT-causing mutations in TyrRS17 (Fig. 1a) and of a role of TyrRS in transcriptional regulation8. We searched for functional changes in mutant TyrRS that are relevant to the disease. We took advantage of having a spectrum of TyrRS variants to build a structure-function relationship that specifically links the unique conformation of the CMT mutants to functional consequences relevant to the neuropathy. These mutations ranged from a rationally designed substitution, through a naturally occurring polymorphism, to CMT-causing mutations. To this end, we established the mechanism of hyperactivation of E2F1 due to aberrant mutant TyrRS interactions and corroborated our findings in patient biosamples (Fig. 1 and Supplementary Fig. 1a-c). However, the ultimate test for the key involvement of this TF in the pathology would come from a disease rescue in an animal model. Targeting E2F1 reduced the toxicity of TyrRS-E196K but was not sufficient in alleviating the motor deficit of the fly CMT model (Fig. 2n, o). Inspired by our transcriptome analysis, which confirmed the involvement of E2F1 but also revealed a much broader transcriptional dysregulation in mutant flies (Fig. 3), we attempted to target TyrRS nuclear localization and achieved a greater success in reducing toxicity and in alleviating motor deficit (Fig. 4c, d). Remarkably, using a genetic approach to prevent mutant TyrRS from entering the nucleus, we achieved a complete rescue at morphological, behavioral, electrophysiological, and transcriptomic levels altogether (Fig. 5), therefore we unequivocally demonstrated the relevance of the nucleus in TyrRS-linked CMT (Fig. 6). We should point out that although targeting E2F1 alone was not sufficient in rescuing the CMT phenotypes, the molecular mechanism we obtained for E2F1 activation by mutant TyrRS provides a clear proof of concept for how the CMT mutants could affect the function of other transcription factors (Supplementary Fig. 1a).

Fig. 6

Schematic illustration of the proposed TyrRS mode of action. TyrRS enters the nucleus and engages with different interaction partners, including transcription factors. CMT-causing mutations do not affect the nuclear translocation of TyrRS. However, when the mutant protein enters the nucleus, these interactions are enhanced or perturbed and new interactions may be formed, leading to dysregulation of the transcriptional machinery. As demonstrated in a Drosophila model, the dysregulation can be alleviated by inhibiting the nuclear entry of TyrRS pharmacologically or genetically

We note that although the overexpression of WT TyrRS does not cause CMT phenotypes in the fly model15,25, the overexpression itself is also associated with extensive transcriptional reprograming (Supplementary Table 1), suggesting that this aaRS is a master regulator of gene transcription in the nucleus. Possibly, the WT TyrRS acts through regulating multiple TFs in a coordinated and balanced manner, yet such balance is disrupted by the CMT mutations. The disruption likely has a hypermorphic component as illustrated by E2F1 hyperactivation and a neomorphic component as suggested by the TFs predicted to be regulated by mutant TyrRS alone (Supplementary Fig. 4c). From a structural perspective, the unique conformational change (Fig. 1b) enhances the capacity of CMT-causing TyrRS mutants to interact with transcription regulators, including but should not be limited to TRIM28 and HDAC1, leading to a change in their functional properties and ultimately triggering a broad dysregulation of gene expression.

The demonstration of nuclear involvement in TyrRS-induced CMT could have important implications for other aaRSs associated with CMT, as all aaRSs were described to localize to the nucleus of the cell and at least two other CMT-linked aaRSs (i.e., MetRS and AlaRS) have known functions in the nucleus37,38. Interestingly, common genetic modifiers with nuclear localization were found in our previous fly-based screens for CMT-associated mutant GlyRS and TyrRS39. This study is facilitated by extensive existing knowledge on the TyrRS system, such as the location of the NLS10 and the acetylation-mediated TyrRS nuclear import31. However, most of this kind of knowledge is lacking for the other CMT-linked aaRS, hindering the evaluation of their possible nuclear involvement at the moment.

Previous works showed that CMT mutations in GlyRS could induce aberrant interactions with ectodomains of membrane receptors (e.g., Nrp1) and intracellular proteins, thereby interfering with proper signaling, as well as trafficking in motor and sensory neurons35,40,41,42,43. Although we saw a complete rescue of disease-relevant phenotypes in the fly by preventing nuclear entry of the mutant TyrRS, we cannot rule out the involvement of other cellular compartments or additional mechanisms in TyrRS-linked CMT. We did confirm, however, that the ΔNLS mutation introduced to TyrRS did not affect the distribution of the protein (WT or E196K) to the extracellular space (Supplementary Fig. 7a) and that the embelin treatment did not affect the secretion of TyrRS (Supplementary Fig. 7b). Therefore, we excluded the possibility that an altered secretion profile of mutant TyrRS contributed to the genetic and the pharmacological rescue of phenotypes in Drosophila. Possibly, the molecules mediating the toxicities outside the nucleus are not as conserved as the mediators inside the nucleus between flies and humans. For example, in contrast to E2F1, there is no direct ortholog of mammalian Nrp1 in Drosophila. Developing a mammalian model for TyrRS-linked CMT would facilitate the evaluation of other potential mechanisms in the future.

As illustrated by the studies on GlyRS-linked CMT and by the network of genes and transcription factors identified in our transcriptome analysis for the mutant TyrRS, aaRS-linked CMT is likely a result of the interplay of multiple molecular pathways—some of them active in the WT condition but dysregulated by the aberrant binding properties of the mutant, while others unique to the mutants alone—and therefore the design of a successful therapeutic approach in the future should be tailored to the pleiotropic mutational impact. Drosophila can be used to test the therapeutic potential of small molecule compounds in a high-throughput manner44. Excitingly, the pharmacological inhibition of TyrRS from entering the nucleus using the PCAF inhibitor embelin mimicked the effect of the genetic restriction and rescued specific disease features in the CMT fly, showing for the first time a successful therapeutic intervention for TyrRS-induced peripheral neuropathy. Although further improvements on drug selection, delivery, and efficacy should be investigated, this work paves the way for developing a viable therapy for CMT patients affected by TyrRS mutations through regulating nuclear trafficking of the translation factor.


Ethical approval

We have complied with all relevant ethical regulations for animal testing and research. The study was approved by the Ethical committee for biomedical experiments with animals of the University of Antwerp (ECD 2014-02). Informed consent was obtained from all individuals included in the study.

Drosophila genetics

The UAS-TyrRS flies were generated and characterized in a previous study15. TyrRSΔNLS cDNA (WT and with CMT mutations) was subcloned into the pUAST transformation vector and was sequence verified. Transgenic flies were generated using standard procedures. For each construct, multiple transgenic lines were established and expression levels were determined by Western blot. The nSyb-Gal4 driver line was kindly provided by M. Leyssen and B. Dickson45. The other Gal4 driver lines and others lines used in the genetic interaction studies were obtained from Bloomington Drosophila Stock Center (Supplementary Table 8). Drosophila crosses were performed at 25 °C, 12 h light/dark cycle, on standard NutriFly medium (FlyStuff).

The fly line Act5C-GAL4/Cyo,GFP was used in the developmental lethality experiments. Act5C-GAL4/Cyo,RFP-Tb was used in the pupation experiment. Adult Drosophila eclosion ratios were determined by the number of Actin-Gal4>transgene versus the number of Balancer/transgene flies. Drosophila pupation was examined by counting the number of Act5C-Gal4>transgene pupae versus the number of Cyo,Tb-RFP>transgene flies.

Cell culture and conditions

The HEK293T (human embryonic kidney) cell line was purchased from ATCC (#CRL-3216, Manassas, VA, USA). Cells were grown in DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco). Cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2.

Upon obtaining written consent, peripheral blood was drawn from CMT patients carrying the E196K or G41R mutations, and control individuals. The sampling procedure was in accordance with the ethical guidelines of the Medical University-Sofia (Bulgaria), the Saint Louis University (USA), and the University of Antwerp (Belgium). Peripheral blood mononuclear cells (PBMC) were isolated on a Ficoll-Paque gradient, transformed with Epstein-Barr virus and incubated at 37 °C for 2 h. After centrifugation, cells were re-suspended in 4 ml RPMI complete medium (Life Technologies) supplemented with 1% phytohaemagglutinin. Cells were seeded on a 24-well plate and incubated at 37 °C, 6% CO2 for a minimum of 3 days. After establishment, cell lines were cultivated in RPMI1640 medium containing 15% fetal calf serum, 1% sodium pyruvate, 1% 200M L-glutamine, and 2% penicillin/streptomycin.

Co-immunoprecipitation and Western blot analysis

Lymphoblast and HEK293T cells were lysed with a radioimmunoprecipitation assay (RIPA) buffer containing 25 mM Tris pH 7.6, NaCl, Sodium Deoxycholate, 0.5% NP40, 0.5% Triton, 0.1% SDS, 5% glycerol. Total lysate was incubated with Dynabeads (Life Technologies) or Protein G beads (Life Technologies) and antibodies raised against TyrRS (Abnova), mouse monoclonal V5 (Thermo Fisher Scientific, R960CUS) or mouse monoclonal E2F1 (Abcam, ab4070). Antibodies against IgG1 (Santa Cruz Biotechnology, sc-2025) were used as a negative control. Input and immunoprecipitate were loaded on non-native PAGE gels (Bio-Rad). The following antibodies were used in the different Western blot experiments: mouse monoclonal V5 (1:5000, Thermo Fisher Scientific, R960CUS), mouse monoclonal TyrRS (1:2000, Abnova, H00008565-M02), rabbit polyclonal TyrRS (1:5000, custom-made), rabbit polyclonal TRIM28 (1:1000, Abcam, ab10484), rabbit monoclonal Flag (1:1000, Sigma-Aldrich, F2555), rabbit polyclonal HA (1:1000, Abcam, ab9110), rabbit polyclonal HDAC1 (1:1000, Cell Signaling technology, #2062), rabbit polyclonal SIRT1 (1:1000, Cell Signaling technology, #2310), rabbit polyclonal E2F1 (1:1000, Abcam, ab112580), rabbit polyclonal acetylated-lysine (1:1000, Cell signaling technology, #9441), GAPDH (1:20000, GeneTex, GTX100118), mouse monoclonal α-Tubulin (1:5000, Abcam, ab7291), mouse monoclonal α-Tubulin (1:3000, Cell Signaling Technology, #3873), mouse monoclonal Lamin A/C (1:1000, Cell Signaling technology, #4777), mouse monoclonal Lamin Dm0 (1:500, Developmental Studies Hybridoma Bank, ADL67.10).

The amount of immunoprecipitated, co-immunoprecipitated, and acetylated protein was determined using the ImageJ software. The amount of co-immunoprecipitated or acetylated protein was normalized to the immunoprecipitated signal, resulting in the ratio of both signals.

Cell fractionation

Nuclear/cytoplasmic fractionation was performed with either the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific) following manufacturer’s instructions or a similar custom protocol46. Briefly, Swelling Buffer (SB) [10 mM Tris-HCl (pH 7.4), 2 mM EDTA, proteinase inhibitor cocktail (added before use)], Plasma Membrane Lysis Buffer (PMLB) [10 mM Tris-HCl (pH 7.1), 2 mM MgCl2, 1% Triton X-100], and Nuclear Extraction Buffer (NEB) [20 mM HEPES (pH 7.6), 300 mM NaCl, 2 mM EDTA, 1 mM 1,4-Dithiothreitol (DTT), 10% glycerol, 1% Triton X-100, protease inhibitor cocktail (added before use)] were prepared. Ice-cold SB was added to the tissue and vortexed at the highest speed for 15 s, followed by incubation on ice for 10 min. Next, ice-cold PMLB (1/20 total volume) was added and vortexed for 5 s and incubated on ice for 1 min. After vortexing for 5 s again, the nuclei were centrifuged at 16,000×g for 5 min at 4 °C. The supernatant (cytoplasm) was transferred to a clean tube and the pellet was washed in PBS, vortexed for 5 s, and the nuclei were centrifuged at 16,000×g for 5 min at 4 °C. The nuclei pellet was then suspended in ice-cold NEB (1/2 of SB volume) and sonicated on ice for 2 × 30 s, with a 30 s pause, using the following settings: cycle 0.5, 10–15% power. Both fractions were then analyzed on Western blot.


Total RNA was isolated from cell lines following standard Trizol (Qiagen) and chloroform extraction protocol followed by ethanol precipitation. The RNA was then treated with the Turbo DNA-free kit (Ambion) to remove the remaining DNA. RNA was transcribed to single strand cDNA with the iScript cDNA synthesis kit (Bio-Rad). Gene expression levels were determined using the power SYBR green PCR master mix (Applied Biosystems) measured and analyzed with the ViiA7 software (Applied Biosystems) and the qBase + software (Biogazelle). Briefly, five housekeeping genes are used to normalize the data. First, the stability of the housekeeping genes was determined between samples. Next, the most stable housekeeping genes were chosen to normalize the expression of the different genes of interest across all samples. The primers used for the RT-qPCR analysis are described in Supplementary Table 9.

Scanning electron microscopy

Adult flies were anesthetised using ether and mounted on aluminum stubs (Electron Microscopy Sciences) without any tissue processing steps. The eyes were coated using a gold sputter and were imaged using scanning electron microscopy (SEM) with an SEM505 microscope (Philips).

Drug screen

Drosophila crosses were performed at 25 °C, 12 h light/dark cycle, on Formula 4–24 Instant Drosophila medium (Carolina) supplemented with 5% inactivated yeast. DMSO (100%) (Sigma-Aldrich) or embelin (Sigma-Aldrich) were added to the medium at a final DMSO concentration of 0.3% (42 mM). Drosophila behavioral assays and pupae formation were performed as described elsewhere.

Drosophila behavioral assays

To assay motor performance of 10-days old flies, climbing speed was assessed with the negative geotaxis assay47. The semi-automated FlyCrawler device (Peira scientific instruments) was used to test and analyze the different genotypes and conditions. Briefly, 10 female flies with shortened wings were shaken down to the bottom of a cylindrical fly container (49 mm diameter). An infrared camera was used to track individual flies and generate videos. Time needed for the first fly to climb from the start of the ascent at the vertical wall to a mark at a height of 82 mm was measured. For each group of 10 flies, the experiment was done 15 times and the average of the 10 fastest walking speeds was calculated. For each genotype and condition, at least 10 groups of 10 flies were tested.

Analysis of the Drosophila larval neuromuscular junction

Morphology of the neuromuscular junction was determined of third instar larvae expressing no transgene (nSyb-Gal4>+), or any of the TyrRS alleles. Third instar larvae fillets were dissected in HL3 buffer and fixed in 3.7% PFA in HL3 for 20 min. After permeabilization and blocking of unspecific epitopes (5% Bovine Serum Albumin), staining of the larval NMJ was performed with the following antibodies: horseradish peroxidase (HRP; Jackson ImmunoResearch Laboratories, 1/2000) and Discs large 1 (dlg1; DHSB, 1/50). Images were taken of muscle 6/7 of either segment 3 or 4 using a Carl Zeiss LSM700 laser scanning confocal microscope with ×20 Plan-Apochromat objective (0.8 NA). Maximum intensity projections of image z-stacks comprising the entire NMJ were analyzed using the Fiji distribution of ImageJ48,49. All boutons were scored using the ImageJ Cell Counter plugin. The length of the neuronal arbor projecting on the muscle was determined using the ImageJ NeuronJ plugin. The arbor was manually traced using the HRP signal.

Dye injections into the giant fiber

The giant fiber dye-injection and imaging methods have previously been described in detail50,51. The R91H05-Gal4 driver was used to drive the expression of the transgene in the giant fiber52,53. Briefly, the GF axons of dissected central nervous systems were injected with tetramethylrhodamine isothiocyanate-Dextran (Sigma) in the cervical connective using a glass electrode (80–100 MΩ) backfilled with 2 M potassium acetate by passing depolarizing current. The samples were fixed in 4% paraformaldehyde, cleared with VECTASHIELD® Antifade Mounting media and scanned at a resolution of 1024 × 1024 pixels, 2.5 × zoom, and 0.5 μm step size with a Nikon A1 plus confocal microscope using a CFI Plan APO lambda 60×/NA1.4 oil objective. Images were processed using Nikon Elements Advance Research 4.

Electrophysiological recordings from the giant fiber circuit

Intracellular recordings from the TTM of adult male and female flies were obtained as previously described54. Briefly, the giant fibers (GFs) were activated with 0.03 ms pulses of 30–60 V using two tungsten electrodes inserted into the brain (Grass S44 stimulator, Grass Instruments). Saline-filled glass electrodes were used for recordings from the TTM and a tungsten electrode in the abdomen served as a ground electrode. The recordings were amplified (Getting 5A amplifier, Getting Instruments) and the signals were stored and analyzed using pCLAMP 10.3 software (Molecular Devices). The ability of the GF to TTM pathway to follow high frequency stimulations was assessed with 10 trains of 10 pulses given at 100 Hz with a 1 s interval between the trains. The average following frequencies were calculated as percent responses.

Total RNA extraction and quality analysis

Total brain RNA was isolated from adult flies aged 10 days after eclosion, the time point at which mutant flies show locomotor impairment. Total RNA was extracted in quadruplicates using the RNAqueous Micro Kit (Ambion Thermo Fisher Scientific) from dissected adult fly brains with the following genotypes nSyb-Gal4>+, nSyb-Gal4> 2xTyrRS-WT, nSyb-Gal4>2xTyrRS-WTΔNLS, nSyb-Gal4>1xTyrRS-E196K, nSyb-Gal4>3xTyrRS-E196KΔNLS. Following extraction, the total RNA was treated with the Turbo DNA-free kit (Ambion Thermo Fisher Scientific), according to manufacturer’s instructions. RNA integrity was assessed using the Eukaryote Total RNA Nano Assay on an Agilent Bioanalyzer 2100 system (Agilent Technologies).

cDNA library construction and next-generation sequencing

Twenty cDNA libraries (4 replicates per condition) were constructed from total RNA using poly(A) enrichment of the mRNA (TruSeq Illumina). Paired-end sequencing data of 75 bp read length, generated on NextSeq 500 (Illumina) in 2 batches of 10 samples each, ranged from 74.3 to 139.4 million reads per sample. The cDNA libraries construction and the RNA sequencing were done at the GENECORE-EMBL Genomic Core Facilities (Germany).

Bioinformatics analysis

The raw reads were trimmed and cleaned of adapters with Trimmomatic v0.32. Sequencing quality was assessed with FASTQC software. After trimming and a low reads filtering step, more than 92% of the reads were used for mapping to Drosophila reference genome (ENSEMBL, BDGP6, release 84) using Tophat v2.0.12. The average percentage of overall mapping of the reads was 84.2%.

Gene expression levels were measured using the counts generated by HTSeq v0.6.1. Given the deep coverage of the transcriptome, the differential expression analysis was performed on all the genetic features listed in the annotation file resulting in 16237 coding and non-coding genes with non-zero counts in at least one of the samples. More than 95% of the protein coding genes in the genome annotation file had non-zero counts in at least one of the samples. The gene expression counts were normalized for all samples together and the biological conditions were compared pairwise using DESeq2 v1.14.1 by including the batch factor in the design55. The PCA and the hierarchical clustering of the regularized log counts revealed 3 outlier samples (nSyb-Gal4>+(11), nSyb-Gal4>TyrRS_WT(12), nSyb-Gal4>TyrRS_WTΔNLS (18)) which were removed from the final differential expression analysis.

Weighted gene co-expression network analysis was performed (WGCNA) to identify gene clusters that share the same expression patterns across the 5 different biological conditions in 17 samples. The regularized log transformed counts from DESeq2 were used to build an unsigned gene co-expression network. The adjacency matrix computed using a soft threshold of 14 resulted from the scale-free topology calculations. PCA and hierarchical clustering on the rlog transformed gene-level counts within that module were additionally performed. WGCNA constructed 39 gene network modules. The highest eigengene significance (correlation between sample trait and eigengene) with a significant p-value was for the magenta module (|0.57|, p-value < 0.02). PCA and hierarchical clustering on the rlog transformed gene-level counts within that module were additionally performed. The genes in magenta module showed a clear separation of TyrRS-E196K from the other analyzed conditions.

Gene ontology enrichment was determined using the functional Gene Set Enrichment Analysis (fgsea)26 using the Drosophila gene ontologies derived from the gsea msigdb (v6.2). We included all Drosophila transcripts (not only protein coding transcripts) in the fgsea analysis. When fold change data was not available, we determined gene ontology enrichment using the DAVID webtool29,30. The iRegulon plugin in Cytoscape was used to detect the transcription factors the targets, and the motifs/tracks associated with the differentially expressed genes.

To calculate and draw custom Venn diagrams the following online tool was used: The representation factor (RF) is the number of overlapping genes divided by the expected number of overlapping genes drawn from two independent groups. A representation factor >1 indicates more overlap than expected of two independent groups, a representation factor <1 indicates less overlap than expected, and a representation factor of 1 indicates that the two groups by the number of genes expected for independent groups of genes. The probability of finding a certain amount of overlapping genes was calculated using the hypergeometric probability formula.

Secretion assay

HEK293T cells were cultured to 70% confluency and then transfected with V5-tagged TyrRS or GlyRS constructs. For experiments to test the effect of embelin on secretion, different doses of Embelin or the solvent control (DMSO) were added into the cell culture medium 30 h after transfection. Cell culture medium was collected 36 h after transfection and then concentrated to 1 ml by passing through EMD Millipore Amicon Ultra-15 filter (Millipore Sigma). The secreted TyrRS or GlyRS in the concentrated medium was pulled down by immunoprecipitation by the V5 antibody and then detected by Western blot analysis.


Measurements were taken from independent samples. We used the GraphPad Prism 7 software, version 7.01, for statistical analyses. Individual tests for each dataset are reported within the figure legends. Reported box plot figures show the median, the box extends from the 25th to the 75th percentiles, and the whiskers depict the 25th and 75th percentile minus and plus 1.5 times the inter-quartile distance, respectively. Reported bar charts show the mean and the error bars as s.e.m. In all figures the p-value is reported as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, non-significant. The effect sizes were calculated using the PlotsOfDifference webtool56. The data points for each experiment were inserted into the web application and the plots were generated using the standard settings. Effect size graphs display the distribution of the differences and the 95% confidence interval is displayed in each graph.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All data generated and/or analyzed during this study are included in this published article (and its supplementary files). The source data underlying Figs. 1c–h, 2m–o, 4a–d, 5a–c, e–h, and Supplementary Figs. 1b, c, 2a, b, 3a–d, 5c, 6a–c, 7a, b are provided as a Source Data file. The RNA sequencing data are deposited at the GEO database (GSE125311). All other relevant data are available from the corresponding authors on reasonable request.


  1. 1.

    Skre, H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin. Genet. 6, 98–118 (1974).

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Meyer-Schuman, R. & Antonellis, A. Emerging mechanisms of aminoacyl-tRNA synthetase mutations in recessive and dominant human disease. Hum. Mol. Genet. 26, R114–R127 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Wei, N., Zhang, Q. & Yang, X. L. Neurodegenerative Charcot-Marie-Tooth disease as a case study to decipher novel functions of aminoacyl-tRNA synthetases. J. Biol. Chem. (2019).

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Azad, A. K., Stanford, D. R., Sarkar, S. & Hopper, A. K. Role of nuclear pools of aminoacyl-tRNA synthetases in tRNA nuclear export. Mol. Biol. Cell 12, 1381–1392 (2001).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Lund, E. & Dahlberg, J. E. Proofreading and aminoacylation of tRNAs before export from the nucleus. Science 282, 2082–2085 (1998).

    CAS  Article  ADS  PubMed  Google Scholar 

  6. 6.

    Popenko, V. I. et al. Compartmentalization of certain components of the protein synthesis apparatus in mammalian cells. Eur. J. Cell Biol. 65, 60–69 (1994).

    CAS  PubMed  Google Scholar 

  7. 7.

    Shi, Y. et al. tRNA synthetase counteracts c-Myc to develop functional vasculature. Elife 3, e02349 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Wei, N. et al. Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damage. Mol. Cell 56, 323–332 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Yannay-Cohen, N. et al. LysRS serves as a key signaling molecule in the immune response by regulating gene expression. Mol. Cell 34, 603–611 (2009).

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Fu, G., Xu, T., Shi, Y., Wei, N. & Yang, X. L. tRNA-controlled nuclear import of a human tRNA synthetase. J. Biol. Chem. 287, 9330–9334 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Gonzaga-Jauregui, C. et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy. Cell Rep. 12, 1169–1183 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Hyun, Y. S. et al. Rare variants in methionyl- and tyrosyl-tRNA synthetase genes in late-onset autosomal dominant Charcot-Marie-Tooth neuropathy. Clin. Genet. 86, 592–594 (2014).

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Jordanova, A. et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat. Genet. 38, 197–202 (2006).

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Froelich, C. A. & First, E. A. Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry 50, 7132–7145 (2011).

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Storkebaum, E. et al. Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy. Proc. Natl Acad. Sci. USA 106, 11782–11787 (2009).

    CAS  Article  ADS  PubMed  Google Scholar 

  16. 16.

    Deneris, E. S. & Hobert, O. Maintenance of postmitotic neuronal cell identity. Nat. Neurosci. 17, 899–907 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Blocquel, D. et al. Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy. Nucleic Acids Res. 45, 8091–8104 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Yang, X. L. et al. Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem. Biol. 14, 1323–1333 (2007).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Leitao-Goncalves, R. et al. Drosophila as a platform to predict the pathogenicity of novel aminoacyl-tRNA synthetase mutations in CMT. Amino Acids 42, 1661–1668 (2012).

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A. & Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 19, 662–671 (2000).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Wang, C., Rauscher, F. J. 3rd, Cress, W. D. & Chen, J. Regulation of E2F1 function by the nuclear corepressor KAP1. J. Biol. Chem. 282, 29902–29909 (2007).

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Wang, C. et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 8, 1025–1031 (2006).

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Wu, T. H. et al. Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition. J. Steroid Biochem. Mol. Biol. 144(Pt B), 253–259 (2014).

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187–17195 (2005).

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Niehues, S. et al. Impaired protein translation in Drosophila models for Charcot-Marie-Tooth neuropathy caused by mutant tRNA synthetases. Nat. Commun. 6, 7520 (2015).

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Sergushichev, A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint at (2016).

  27. 27.

    Janky, R. et al. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput. Biol. 10, e1003731 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinforma. 9, 559 (2008).

    Article  CAS  Google Scholar 

  29. 29.

    Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).

    Article  CAS  Google Scholar 

  30. 30.

    Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Cao, X. et al. Acetylation promotes TyrRS nuclear translocation to prevent oxidative damage. Proc. Natl Acad. Sci. USA 114, 687–692 (2017).

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Modak, R. et al. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor. ACS Chem. Biol. 8, 1311–1323 (2013).

    CAS  Article  ADS  PubMed  Google Scholar 

  33. 33.

    Atkinson, D. et al. Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy. Neurology 88, 533–542 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Spaulding, E. L. et al. Synaptic deficits at neuromuscular junctions in two mouse models of charcot-marie-tooth type 2d. J. Neurosci. 36, 3254–3267 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    He, W. et al. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature 526, 710–714 (2015).

    CAS  Article  ADS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Motley, W. W. et al. Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels. PLoS Genet. 7, e1002399 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Sun, L., Song, Y., Blocquel, D., Yang, X. L. & Schimmel, P. Two crystal structures reveal design for repurposing the C-Ala domain of human AlaRS. Proc. Natl Acad. Sci. USA 113, 14300–14305 (2016).

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Ko, Y. G., Kang, Y. S., Kim, E. K., Park, S. G. & Kim, S. Nucleolar localization of human methionyl-tRNA synthetase and its role in ribosomal RNA synthesis. J. Cell Biol. 149, 567–574 (2000).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Ermanoska, B. et al. CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in Drosophila. Neurobiol. Dis. 68, 180–189 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Grice, S. J., Sleigh, J. N. & Zameel Cader, M. Plexin-semaphorin signaling modifies neuromuscular defects in a Drosophila model of peripheral neuropathy. Front. Mol. Neurosci. 11, 55 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Sleigh, J. N. et al. Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis. Sci. Rep. 7, 9216 (2017).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Benoy, V. et al. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain 141, 673–687 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Mo, Z. et al. Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy. Nat. Commun. 9, 1007 (2018).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Chang, S. et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256–263 (2008).

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Pauli, A. et al. Cell-type-specific TEV protease cleavage reveals cohesin functions in Drosophila neurons. Dev. Cell 14, 239–251 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Shi, Y., Wei, N. & Yang, X. L. Studying nuclear functions of aminoacyl tRNA synthetases. Methods 113, 105–110 (2017).

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Strauss, R. & Heisenberg, M. A higher control center of locomotor behavior in the Drosophila brain. J. Neurosci. 13, 1852–1861 (1993).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).

    CAS  Article  Google Scholar 

  49. 49.

    Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Boerner, J. & Godenschwege, T. A. Application for the Drosophila ventral nerve cord standard in neuronal circuit reconstruction and in-depth analysis of mutant morphology. J. Neurogenet. 24, 158–167 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Boerner, J. & Godenschwege, T. A. Whole mount preparation of the adult Drosophila ventral nerve cord for giant fiber dye injection. J. Vis. Exp. (2011).

  52. 52.

    Pfeiffer, B. D. et al. Tools for neuroanatomy and neurogenetics in Drosophila. Proc. Natl Acad. Sci. USA 105, 9715–9720 (2008).

    CAS  Article  ADS  Google Scholar 

  53. 53.

    Lee, L. H. & Godenschwege, T. A. Structure-function analyses of tyrosine phosphatase PTP69D in giant fiber synapse formation of Drosophila. Mol. Cell Neurosci. 64, 24–31 (2015).

    CAS  Article  PubMed  Google Scholar 

  54. 54.

    Allen, M. J. & Godenschwege, T. A. Electrophysiological recordings from the Drosophila giant fiber system (GFS). Cold Spring Harb. Protoc. 2010, pdb prot5453 (2010).

  55. 55.

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Goedhart, J. PlotsOfDifferences–a web app for the quantitative comparison of unpaired data. Preprint at (2019).

Download references


We would like to thank Ricardo Leitao-Gonçalves for balancing the Drosophila lines; Tinne Ooms, and Els De Vriendt for the technical assistance. We acknowledge the service of the Genomics Core Facility of EMBL, Heidelberg, Germany for the RNA sequencing performed. This work was supported in part by the US National Institutes of Health (R01-NS085092 and R01-GM088278 to X.-L.Y.), the US National Institute for Neurological Disease and Stroke (R15NS090043 to T.G.), the Research Fund of the University of Antwerp (TOP-BOF-29069 to A.J.), the Fund for Scientific Research–Flanders (FWO) (G078414N to A.J.) and the AFM-Telethon, France (16197 to A.J.). S.B., B.E., and M.-L.E. obtained fellowships from the Fund for Scientific Research-Flanders. N.W. was supported in part by a fellowship from National Foundation for Cancer Research. S.Y.-M. is the recipient of a DdT2 fellowship from the AFM-Telethon, France. P.K. and T.P. were supported by the Jupiter Life Sciences Initiative of Florida Atlantic University.

Author information




S.B., N.W., A.J., and X.-L.Y. initiated and conceptualized the project. S.B., N.W., M.-L.E., B.E., S.Y.-M., D.B., P.K., T.P., and T.G. performed and analyzed the experiments. F.P.T., V.G., and I.T. aided in patient recruitment and collection of material. L.M. analyzed the RNAseq data and B.A. analyzed the microscopy data. S.B. wrote the original draft, while S.B., N.W., M.-L.E., B.E., S.Y.-M., L.M., B.A., D.B., F.P.T., V.G., I.T., A.J., and X.-L.Y. revised the paper. The work was performed under the supervision of M.-L.E., A.J., and X.-L.Y. A.J. and X.-L.Y. gathered funding.

Corresponding authors

Correspondence to Albena Jordanova or Xiang-Lei Yang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Source data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bervoets, S., Wei, N., Erfurth, ML. et al. Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy. Nat Commun 10, 5045 (2019).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing